Biotechnology
Swiss companies specializing in biotechnology
Biotechnology firms research and develop new medical therapies or agricultural processes. Clinical trial outcomes and regulatory decisions routinely drive extreme price action and liquidity across this industry. Currently, Moderna, Inc. ranks as the top gainer, and MindMaze Therapeutics Holding SA sees maximum volume. The technical and fundamental metrics provided below help quantify these sudden shifts.
Symbol | Mkt cap | Price | Chg % | Vol | Rel vol | P/E | EPS dil TTM | EPS dil growth TTM YoY | Div yield % TTM | Sector | Analyst rating |
|---|---|---|---|---|---|---|---|---|---|---|---|
 AMGAmgen Inc. | 211.44 B CHF | 388.337 CHF | +1.70% | 9 | 0.76 | 26.94 | 14.41 CHF | +39.89% | 2.08% | Health technology | Neutral |
 GISGilead Sciences, Inc. | 176.9 B CHF | 134.099 CHF | −5.57% | 20 | 0.15 | — | −2.63 CHF | −151.18% | 1.86% | Health technology | Buy |
 0QFModerna, Inc. | 84.32 B CHF | 214.368 CHF | +8.91% | 2.19 K | 10.49 | — | −6.45 CHF | −8.21% | 0.00% | Health technology | Neutral |
| MRNAModerna, Inc. | 84.32 B CHF | 161.56 CHF | −20.41% | 8 | — | — | −6.45 CHF | −8.21% | 0.00% | Health technology | Neutral |
| MRNA.USDModerna, Inc. | 84.32 B CHF | 226.80 USD | 0.00% | 1.93 K | 1.55 | — | −6.45 CHF | −6.20% | 0.00% | Health technology | Neutral |
 CSJCSL Limited | 54.2 B CHF | 113.768 CHF | −1.02% | 386 | 1.17 | — | −4.25 CHF | −186.00% | 2.05% | Health technology | Buy |
 LONNLonza Group AG | 45.09 B CHF | 663.4 CHF | −1.34% | 212.06 K | 1.42 | — | −1.55 CHF | −115.18% | 0.76% | Health technology | Buy |
| LO3Lonza Group AG | 45.09 B CHF | 658.428 CHF | −2.15% | 34 | 0.12 | — | −1.55 CHF | −115.18% | 0.76% | Health technology | Buy |
 22UABioNTech SE Sponsored ADRDR | 18.62 B CHF | 70.648 CHF | −5.05% | 33 | 0.78 | — | −6.34 CHF | −399.64% | 0.00% | Health technology | Buy |
 HDP1Arrowhead Pharmaceuticals, Inc. | 7.12 B CHF | 50.112 CHF | −7.82% | 2 K | 17.39 | — | −1.81 CHF | −80.90% | 0.00% | Health technology | Strong buy |
 1CGCRISPR Therapeutics AG | 4.11 B CHF | 40.056 CHF | −2.75% | 600 | 1.15 | — | −3.97 CHF | +10.71% | 0.00% | Health technology | Buy |
 IOVAIovance Biotherapeutics Inc | 3.22 B CHF | 7.100 CHF | −40.91% | 300 | — | — | −0.58 CHF | +40.09% | 0.00% | Health technology | Buy |
 RXRXRecursion Pharmaceuticals, Inc. Class A | 1.98 B CHF | 3.117 CHF | −4.45% | 4 K | 5.28 | — | −0.75 CHF | +48.25% | 0.00% | Health technology | Buy |
 NVV1Novavax, Inc. | 1.44 B CHF | 8.008 CHF | −3.65% | 500 | 1.61 | — | −1.23 CHF | −168.74% | 0.00% | Health technology | Buy |
 PPGNPolyPeptide Group AG | 1.36 B CHF | 40.05 CHF | −1.11% | 21.45 K | 0.97 | 99.08 | 0.40 CHF | — | 0.00% | Health technology | Neutral |
| PPPGNEPolyPeptide Group AG TEMP | 1.36 B CHF | 44.00 CHF | +0.34% | 1.97 K | 0.19 | 108.86 | 0.40 CHF | — | 0.00% | Health technology | No rating |
| 8H0PolyPeptide Group AG | 1.36 B CHF | 43.866 CHF | −0.37% | 400 | 0.36 | 108.53 | 0.40 CHF | — | 0.00% | Health technology | Neutral |
 BIOVBioVersys AG | 132.56 M CHF | 22.4 CHF | 0.00% | 2.86 K | 0.97 | — | −4.51 CHF | −29.97% | 0.00% | Health technology | Strong buy |
 6MLMolecular Partners AG | 104.97 M CHF | 2.617 CHF | +1.16% | 80 | 0.64 | — | −1.35 CHF | +16.86% | 0.00% | Health technology | Strong buy |
| MOLNMolecular Partners AG | 104.97 M CHF | 2.60 CHF | −0.76% | 73.19 K | 2.14 | — | −1.35 CHF | +16.86% | 0.00% | Health technology | Strong buy |
 MMTXMindMaze Therapeutics Holding SA | 25.06 M CHF | 0.1342 CHF | −1.76% | 1.01 M | 1.17 | — | — | — | 0.00% | Health technology | No rating |